NEW YORK (GenomeWeb News) – Illumina and Laboratory Corporation of America have signed a multi-year supply agreement for Illumina's next-gen sequencing instruments and microarray equipment, the companies said today.

The deal gives LabCorp expanded rights to use Illumina's instruments to develop, validate, and market laboratory-developed tests to clinicians in the US and Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.